COO

ACCE thesis

Cooper manufactures soft contact lenses through CooperVision and surgical fertility devices through CooperSurgical, two businesses that look nothing alike but share the same distribution muscle and MedTech pricing power. CooperVision's daily silicone hydrogel lenses - particularly the MyDay and clariti franchises - sit inside a global contact lens market growing mid-single digits annually, with myopia management products like MiSight commanding premium pricing as childhood myopia becomes a genuine public health crisis. The fertility segment is the less-discussed angle: CooperSurgical controls roughly 40% of the IVF consumables market after the 2022 Generate Life Sciences acquisition, locking in recurring revenue tied to procedure volumes that are structurally growing as women delay childbirth. The disconnect between the trailing PE of 57.5x and forward PE of 14.5x signals either a one-time earnings distortion or a sharp acceleration consensus is pricing in - that gap demands investigation before dismissal. Operating margin sitting at -2.9% trailing while gross margins hold at 65.5% tells you the earnings power is there; the question is whether management executes on the cost structure fast enough to justify the $13.2B market cap.